What was the Medpace lead plaintiff deadline?

According to the public investor notices, the deadline to ask the court to be appointed lead plaintiff was June 8, 2026, which has now passed. Investors who did not seek lead-plaintiff status may still be part of any class if one is certified; missing the lead-plaintiff deadline does not by itself remove an investor from a future class.

Medpace Securities Class Action (MEDP)

Q: Is there a Medpace settlement or claim form for this securities lawsuit?

No. Durbin v. Medpace Holdings, Inc. is a newly filed securities-fraud complaint. There is no certified class, no settlement, and no claim form. The allegations are unproven and Medpace has not been found liable.

Q: Who could be covered by the proposed Medpace investor class?

The complaint proposes a class of investors who purchased or acquired Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive. Class membership is not finalized; a court must still rule on certification.

Q: What does the Medpace securities lawsuit allege?

The complaint alleges Medpace and certain executives made materially misleading statements that overstated the company's projected book-to-bill ratio, described backlog cancellations as well behaved, and misrepresented the breadth of its third-quarter revenue outperformance and the concentration of its pre-backlog work — until Medpace's February 9, 2026 release of a 1.04 book-to-bill ratio and its February 10, 2026 earnings call disclosing the highest cancellations in over a year revealed the truth and the stock fell sharply. These are unproven allegations.

Q: Do I need to do anything to join the Medpace class action?

No. At this stage there is nothing to file. Investors who took no action may remain potential class members, subject to the eventual class definition, the court's certification ruling, any exclusion requests, and any later claims process; if a settlement is ever reached, class members would typically need to submit a valid claim form to be paid. The only investors who needed to act were those who wanted to seek appointment as lead plaintiff, by the June 8, 2026 deadline that has now passed.

By Steve Levine

Medpace Holdings (MEDP) securities class action over backlog cancellation disclosures

Published: June 17, 2026

▼ Allegations Only · No Settlement Yet

This article describes a securities class action complaint. The statements below are unproven allegations. Medpace Holdings, Inc. has not been found liable, there is no certified class, and nothing to claim at this time. This page is informational and is not legal or investment advice.

Status Complaint Filed Durbin v. Medpace Holdings, Inc., No. 1:26-cv-00346 (S.D. Ohio)

Proposed Class Period April 22, 2025 – February 9, 2026 Purchasers of Medpace (NASDAQ: MEDP) common stock

Lead Plaintiff Deadline June 8, 2026 (passed) Date to ask the court to lead the case; not required to be a class member

Can I Claim? No — nothing to claim yet

What Is This About?

A securities-fraud class action complaint, captioned Durbin v. Medpace Holdings, Inc., No. 1:26-cv-00346, was filed on April 6, 2026 in the U.S. District Court for the Southern District of Ohio against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its senior officers. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Medpace common stock between April 22, 2025 and February 9, 2026.

Medpace is a clinical contract research organization (CRO) that runs clinical trials for biotechnology, pharmaceutical, and medical-device companies. Like most CROs, it is closely watched for its "book-to-bill" ratio — a measure of new business awards relative to revenue — and for the level of cancellations in its trial backlog, both of which signal future revenue. The complaint alleges that, during the class period, Medpace and its executives overstated the company's projected book-to-bill ratio, described backlog cancellations as well behaved, and misrepresented the breadth of its third-quarter revenue outperformance and the concentration of its pre-backlog work in the metabolic area. The allegations are unproven. As of the latest publicly accessible docket update, Medpace had not filed a substantive response to the complaint; the company acknowledged the lawsuit in its first-quarter 2026 Form 10-Q and said it had not recognized a related liability because any loss was not currently probable or reasonably estimable.

What Allegedly Happened

According to the complaint, management repeatedly pointed investors toward a projected book-to-bill ratio of about 1.15 for the back half of 2025 and characterized backlog cancellations as well behaved on its quarterly earnings calls. The case alleges those statements understated the risk that cancellations could spike — a risk the complaint says materialized in the fourth quarter, with cancellations concentrated in the metabolic therapeutic area that had been a growth driver. The complaint also points to an October 2025 statement that the quarter's revenue outperformance was broad-based and not isolated to a handful of studies, alongside an acknowledgment that the company's pre-backlog work was over-indexed toward metabolic trials.

The alleged truth reached the market in two steps. After the close on February 9, 2026, Medpace issued a press release reporting a fourth-quarter 2025 book-to-bill ratio of 1.04 — well below the 1.15 investors had been led to expect. On the February 10, 2026 earnings call, the complaint says CEO August Troendle disclosed that backlog cancellations, in both absolute and percentage terms, were the highest in more than a year, and that they had been skewed toward the metabolic area. MEDP shares fell more than 15.9%, from a $530.35 close on February 9, 2026 to $446.05 on February 10, 2026. The complaint frames the disclosures as revealing the deterioration that had allegedly been concealed, and seeks to recover losses for investors who purchased during the proposed class period. Whether any of these allegations can be proven remains to be decided by the court.

After the close of the proposed class period, Medpace's reported results continued to weaken. In its first-quarter 2026 results released on April 22, 2026, the company reported a book-to-bill ratio of 0.88, and it disclosed that President Jesse Geiger had notified the company on April 21, 2026 of his intent to resign and retire effective May 31, 2026 — stating that his departure was not the result of any disagreement over the company's operations, policies, or practices. MEDP shares closed down about 22.6% on April 23, 2026, at $393.42. These developments are subsequent to the proposed class period and the February 2026 disclosures at the center of the complaint, and are described here for context.

Who Is Affected

The proposed class consists of investors who purchased or otherwise acquired Medpace Holdings, Inc. (NASDAQ: MEDP) common stock during the proposed class period of April 22, 2025 through February 9, 2026, inclusive. No class has been certified yet, so membership is not final. This is an investor case — it concerns statements made to shareholders and the price of MEDP stock, not Medpace's clinical-trial services, sponsors, or employees.

What Happens Next

This case is at the earliest stage. Under the Private Securities Litigation Reform Act, the public investor notices set a deadline of June 8, 2026 for investors to ask the court to be appointed lead plaintiff — the investor, often an institution with a large loss, who directs the litigation on behalf of the class. That deadline has now passed. An investor did not need to file a lead-plaintiff motion to remain a potential absent class member; investors who took no action may still be covered if a class is later certified, subject to the eventual class definition, the court's certification ruling, any exclusion requests, and any later claims process.

From here, the court is expected to consider any timely lead-plaintiff motions and appoint a lead plaintiff and lead counsel, after which an amended complaint is typically filed and the defendants usually respond by moving to dismiss. Securities class actions commonly involve substantial motion practice and may take years to resolve, with no guarantee of certification, settlement, or recovery. There is no settlement and no claim form at this time. If a settlement is ever reached, OpenClassActions will update this page with the deadline, fund amount, and filing instructions.

Frequently Asked Questions

Is there a settlement or claim form yet?

No. This is a newly filed complaint. There is no certified class, no settlement, and no claim form. Nothing can be claimed at this stage.

Who is in the proposed class?

Investors who purchased or acquired Medpace (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive. The class is not finalized — a court must still rule on certification.

What does the lawsuit allege?

That Medpace and certain executives made materially misleading statements that overstated the company's projected book-to-bill ratio, described backlog cancellations as well behaved, and misrepresented the breadth of its third-quarter revenue outperformance and the concentration of its pre-backlog work — until Medpace's February 9, 2026 release of a weaker 1.04 book-to-bill ratio and the February 10, 2026 earnings call disclosing the highest cancellations in over a year revealed the truth and the stock fell sharply. These are unproven allegations.

What was the lead plaintiff deadline?

The public investor notices listed June 8, 2026 as the deadline to move for appointment as lead plaintiff. That date has passed. Seeking lead-plaintiff status was optional and was not required to remain part of any certified class.

Do I need to do anything right now?

No. There is nothing to file at this stage. Investors who took no action may remain potential class members, subject to the eventual class definition, the court's certification ruling, any exclusion requests, and any later claims process. If a settlement is ever reached, class members would typically need to submit a valid claim form to receive a payment.

Read the Class Action Complaint

The full complaint filed in Durbin v. Medpace Holdings, Inc., No. 1:26-cv-00346-SJD (S.D. Ohio), is available below. If the document viewer does not load on your device, use the download link beneath it to open the full PDF.

Download the Full Class Action Complaint (PDF)